Xiangjun Kong

Xiangjun Kong is a Principal Scientist at Neogene Therapeutics, having progressed through roles from Scientist to Senior Scientist since joining in January 2020. Prior to this, Xiangjun Kong served as a Postdoctoral Fellow at The Netherlands Cancer Institute from October 2013 to December 2019, focusing on high-throughput genetic screening to explore cancer drug addiction and resistance to immunotherapy, particularly utilizing whole genome CRISPR/Cas9 screening techniques. Educationally, Xiangjun Kong earned a PhD in Cell/Cellular and Molecular Biology from the University of Science and Technology of China in 2013 and holds a Bachelor's degree in Tea Science from Anhui Agricultural University obtained in 2007.